Timing of curative treatment for prostate cancer: A systematic review

European Urology

Volumn 64, Issue 2, 2013, Pages 204-215

  Van Den Bergh, Roderick C N ^a,b   Albertsen, Peter C ^c   Bangma, Chris H ^d   Freedland, Stephen J ^e   Graefen, Markus ^f   Vickers, Andrew ^g   Van Der Poel, Henk G ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e DURHAM VA MEDICAL CENTER   (United States)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Active surveillance; Delay; Expectant management; Outcomes; Prostate cancer; Radiation therapy; Radical prostatectomy

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; DISTANT METASTASIS; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SYSTEMATIC REVIEW; THERAPY DELAY;

ACTIVE SURVEILLANCE; DELAY; EXPECTANT MANAGEMENT; OUTCOMES; PROSTATE CANCER; RADIATION THERAPY; RADICAL PROSTATECTOMY;

EARLY DETECTION OF CANCER; HUMANS; MALE; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; TIME FACTORS; TIME-TO-TREATMENT; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84879964985     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.02.024     Document Type: Review

References (47)

1. G.S. Kulkarni, D.R. Urbach, P.C. Austin, N.E. Fleshner, and A. Laupacis Longer wait times increase overall mortality in patients with bladder cancer J Urol 182 2009 1318 1324
2. J. Huang, L. Barbera, M. Brouwers, G. Browman, and W.J. Mackillop Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review J Clin Oncol 21 2003 555 563
3. N. O'Rourke, and R. Edwards Lung cancer treatment waiting times and tumour growth Clin Oncol (R Coll Radiol) 12 2000 141 144
4. F.H. Schröder, J. Hugosson, and M.J. Roobol Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981 990
5. G. Draisma, R. Boer, and S.J. Otto Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomised Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868 878
6. M.A. Dall'era, P.C. Albertsen, and C. Bangma Active surveillance for prostate cancer: a systematic review of the literature Eur Urol 62 2012 976 983
7. R.C. van den Bergh, S. Roemeling, and M.J. Roobol Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly Eur Urol 55 2009 1 8
8. A. Liberati, D.G. Altman, and J. Tetzlaff The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration PLoS Med 6 2009 e1000100
9. M.R. Abern, W.J. Aronson, and M.K. Terris Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database Prostate 73 2013 409 417
10. S.F. Andrews, E.M. Horwitz, and S.J. Feigenberg Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma? Cancer 104 2005 299 304
11. M.A. Dall'Era, J.E. Cowan, and J. Simko Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment BJU Int 107 2011 1232 1237
12. M. Graefen, J. Walz, K.H. Chun, T. Schlomm, A. Haese, and H. Huland Reasonable delay of surgical treatment in men with localized prostate cancer - impact on prognosis? Eur Urol 47 2005 756 760
13. B. Holmström, E. Holmberg, and L. Egevad Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study J Urol 184 2010 1322 1327
14. M.A. Khan, L.A. Mangold, J.I. Epstein, J.K. Boitnott, P.C. Walsh, and A.W. Partin Impact of surgical delay on long-term cancer control for clinically localized prostate cancer J Urol 172 2004 1835 1839
15. R. Korets, C.M. Seager, M.S. Pitman, G.W. Hruby, M.C. Benson, and J.M. McKiernan Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis BJU Int 110 2012 211 216
16. W. Kwan, T. Pickles, G. Duncan, M. Liu, and C. Paltiel Relationship between delay in radiotherapy and biochemical control in prostate cancer Int J Radiat Oncol Biol Phys 66 2006 663 668
17. D.K. Lee, V. Allareddy, M.A. O'Donnell, R.D. Williams, and B.R. Konety Does the interval between prostate biopsy and radical prostatectomy affect the immediate postoperative outcome? BJU Int 97 2006 48 50
18. R.K. Nam, M.A. Jewett, and M.D. Krahn Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy Can J Urol 10 2003 1891 1898
19. P.L. Nguyen, R. Whittington, and S. Koo The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate carcinoma Cancer 103 2005 2053 2059
20. D. O'Brien, S. Loeb, and G.F. Carvalhal Delay of surgery in men with low risk prostate cancer J Urol 185 2011 2143 2147
21. J.J. Phillips, M.C. Hall, W.R. Lee, and P.E. Clark Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer? Urol Oncol 25 2007 196 200
22. M. Sun, F. Abdollah, and J. Hansen Is a treatment delay in radical prostatectomy safe in individuals with low-risk prostate cancer? J Sex Med 9 2012 2961 2969
23. R.C. van den Bergh, E.W. Steyerberg, and A. Khatami Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer 116 2010 1281 1290
24. A.J. Vickers, F.J. Bianco Jr., S. Boorjian, P.T. Scardino, and J.A. Eastham Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence? Cancer 106 2006 576 580
25. C. Warlick, B.J. Trock, P. Landis, J.I. Epstein, and H.B. Carter Delayed versus immediate surgical intervention and prostate cancer outcome J Natl Cancer Inst 98 2006 355 357
26. S.A. Boorjian, F.J. Bianco Jr., P.T. Scardino, and J.A. Eastham Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy? BJU Int 96 2005 773 776
27. S.J. Freedland, C.J. Kane, and C.L. Amling Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer J Urol 175 2006 1298 1302
28. A. Khatami, J.E. Damber, P. Lodding, C.G. Pihl, and J. Hugosson Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy? A case control study Scand J Urol Nephrol 37 2003 213 217
29. A. Shibata, U.M. Mohanasundaram, and M.K. Terris Interval from prostate biopsy to radical prostatectomy: effect on PSA, Gleason sum, and risk of recurrence Urology 66 2005 808 813
30. A.V. D'Amico, J.W. Moul, P.R. Carroll, L. Sun, D. Lubeck, and M.H. Chen Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure J Natl Cancer Inst 96 2004 509 515
31. A. Vickers, C. Bennette, and G. Steineck Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial Eur Urol 62 2012 204 209
32. G.L. Lu-Yao, P.C. Albertsen, and D.F. Moore Outcomes of localized prostate cancer following conservative management JAMA 302 2009 1202 1209
33. T.J. Wilt, M.K. Brawer, and K.M. Jones Radical prostatectomy versus observation for localized prostate cancer N Engl J Med 367 2012 203 213
34. R.A. Godtman, E. Holmberg, A. Khatami, J. Stranne, and J. Hugosson Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial Eur Urol 63 2013 101 107
35. J.I. Epstein, Z. Feng, B.J. Trock, and P.M. Pierorazio Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades Eur Urol 61 2012 1019 1024
36. V. Iremashvili, L. Pelaez, M. Manoharan, M. Jorda, D.L. Rosenberg, and M.S. Soloway Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols Eur Urol 62 2012 462 468
37. R.K. Berglund, T.A. Masterson, K.C. Vora, S.E. Eggener, J.A. Eastham, and B.D. Guillonneau Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance J Urol 180 2008 1964 1968
38. King AC, Livermore A, Laurila TA, Huang W, Jarrard DF. Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer. Urol Oncol. In press.
39. M. Bul, X. Zhu, and R. Valdagni Active surveillance for low-risk prostate cancer worldwide: the PRIAS study Eur Urol 63 2013 597 603
40. J. Donovan, N. Mills, and M. Smith Quality improvement report: improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult BMJ 325 2002 766 770
41. J. Xia, B.J. Trock, and M.R. Cooperberg Prostate cancer mortality following active surveillance versus immediate radical prostatectomy Clin Cancer Res 18 2012 5471 5478
42. L. Radomski, J. Gani, G. Trottier, and A. Finelli Active surveillance failure for prostate cancer: does the delay in treatment increase the risk of urinary incontinence? Can J Urol 19 2012 6287 6292
43. K. Fujita, P. Landis, B.K. McNeil, and C.P. Pavlovich Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance J Urol 182 2009 2664 2669
44. R.E. Gray, M.I. Fitch, C. Phillips, M. Labrecque, and L. Klotz Presurgery experiences of prostate cancer patients and their spouses Cancer Pract 7 1999 130 135
45. R.C. van den Bergh, M.L. Essink-Bot, and M.J. Roobol Anxiety and distress during active surveillance for early prostate cancer Cancer 115 2009 3868 3878
46. A. Heidenreich, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 2011 61 71
47. I. Thompson, J.B. Thrasher, and G. Aus Guideline for the management of clinically localized prostate cancer: 2007 update J Urol 177 2007 2106 2131